

Bharat Biotech and Bilthoven Biologicals B.V. Announce Collaboration to Produce and Supply Oral Polio Vaccines

Hyderabad, India / Netherlands, 2nd April 2024: Bharat Biotech, a global leader in vaccine and biotherapeutic innovation, also the largest manufacturer of oral polio vaccines, and Bilthoven Biologicals B.V., (BBio), a wholly owned subsidiary of Serum Institute of India Private Limited, based in Netherlands, announced a collaboration today, to further strengthen the production and supply security of Oral Polio Vaccines (OPV).

A requisite Agreement has been signed between BBIL and BBio wherein BBIL will procure drug substances for the production of oral polio vaccines to be supplied within India and globally.

Through this collaboration, BBIL and BBio will jointly obtain the regulatory approvals and licenses required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at Bilthoven Biologicals.

Adar Poonawalla, CEO of Serum Institute of India, said, “We are delighted to join forces with Bharat Biotech to reinforce the global supply of polio vaccines. Our vision is to eradicate Polio worldwide, taking a crucial step towards reducing the impact of this deadly disease on vulnerable populations.”

Dr. Krishna Ella, Executive Chairman of Bharat Biotech, said, “Oral polio vaccines have been an integral part of the Govt of India’s Universal Immunisation Program (UIP) for several decades, with Bharat Biotech being one of the largest suppliers to immunisation programs across the world. This collaboration between BBIL and BBio exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation’s mission to eradicate polio”

As we approach the critical phase of global polio eradication, this collaboration will support the effort to create a polio-free world.

=====XXXX=====

About Serum Institute of India:

Serum Institute of India Pvt. Ltd, is a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. Present across 170+ countries, including the US, UK, and Europe, SII holds the distinction of being the world's largest vaccine manufacturer. SII's multifunctional production and one-of-the-largest facility in Manjri, Pune, with an annual capacity of 4 billion doses, has saved over 30 million lives over the years.

Founded in 1966, SII's primary mission is to produce life-saving immunobiological drugs, with a particular emphasis on affordability and accessibility. Guided by a strong commitment to improving global health, the company has played a pivotal role in reducing the prices of essential vaccines, such as Diphtheria, Tetanus, Pertussis, HIB, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. Notably, they are the manufacturers of 'Pneumosil,' the world's most affordable PCV, and 'Cervavac' the first indigenous qHPV vaccine in India. Moreover, SII has been at the forefront of the global fight against COVID-19, delivering over 2 billion doses of the COVID-19 vaccine worldwide.

To further expand its global presence and ensure widespread vaccine availability, SII has established Serum Life Sciences Ltd, a subsidiary in the UK. Through relentless pursuit of innovation, SII continues to champion the cause of affordable vaccines, making a positive impact on the lives of millions worldwide.
www.seruminstitute.com

About Bilthoven Biologicals

Bilthoven Biologicals emerged after privatizing NVI, formerly part of RIVM. The Cyrus Poonawalla Group acquired the vaccine producing part of NVI in 2012 and founded Bilthoven Biologicals. Serum Institute of India made its first international acquisition by acquiring Bilthoven Biologicals, a bioengineering and pharmaceutical company from The Netherlands Government on 29th June 2012. The takeover ensures access to technology and expertise for making the IPV (Injectable Polio Vaccine, Salk), earlier possessed by only 3 other vaccine manufacturers. Bilthoven Biologicals is spread over 40 acres with an installed manufacturing capacity of over 20 million doses of vaccines annually. The production facilities are State-of-art and fully compliant with cGMP and biopharmaceutical requirements.

The acquisition enhances Serum Institute's offerings in the paediatric vaccine segment and with this Serum Institute hopes to make a significant contribution to



Bilthoven Biologicals
Cyrus Poonawalla Group



the eradication of Polio from the World. The takeover also provides an important manufacturing base in Europe, with access to strategic European Markets.

About Bharat Biotech:

Bharat Biotech (BBIL) is a biotech company in Genome Valley, Hyderabad, India. BBIL is a global leader with 145 patents, ~20 vaccines and bio-therapeutics, and registrations in 125 countries. These vaccines developed with clinical trials in more than 20 countries worldwide and more than 100 publications in peer reviewed journals. The company has manufactured and supplied more than 9 billion doses of vaccines globally, saving millions of lives and livelihoods annually.

The company has world-class vaccine and bio-therapeutics research, product development, manufacturing, and distribution facilities. BBIL has developed vaccines for infectious diseases, including Hepatitis B, Pentavalent (DPT+HepB+Hib), Rabies, Typhoid, polio, H1N1 influenza, Japanese Encephalitis (JENVAC[®]), India's first Rotavirus vaccine, the world's first Typhoid conjugate vaccine, TYPBAR TCV[®], novel vaccines for covid-19 such as COVAXIN[®] and INCOVACC[®]. BBIL introduced WHO pre-qualified vaccines namely BIOPOLIO[®], ROTAVAC[®], ROTAVAC 5D[®], and TYPBAR TCV[®] in several countries worldwide.

BBIL has a strong pipeline of innovative vaccines against Malaria, Cholera, Tuberculosis, Paratyphi A, Non-Typhoidal Salmonella, Chikungunya, Zika, etc. The acquisition of Chiron Behring Vaccines has positioned Bharat Biotech as one of the world's largest rabies vaccine manufacturers with CHIRORAB[®] and INDIRAB[®]. Visit www.bharatbiotech.com.

For more information, please contact:

Bilthoven Biologicals B.V.:

Mayank Sen - mayank.sen@seruminstitute.com +91 986 797 4055

Bharat Biotech:

Sheela Panicker - enright@enrightpr.com +91 984 980 9594